Increased levels of urinary PGE-M, a biomarker of inflammation, occur in association with obesity, aging, and lung metastases in patients with breast cancer

Cancer Prevention Research

Volumn 6, Issue 5, 2013, Pages 428-436

  Morris, Patrick G ^a   Zhou, Xi Kathy ^b   Milne, Ginger L ^c   Goldstein, Daniel ^a   Hawks, Laura C ^a   Dang, Chau T ^a   Modi, Shanu ^a   Fornier, Monica N ^a   Hudis, Clifford A ^a   Dannenberg, Andrew J ^b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c VANDERBILT UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOTOXIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN E2;

ADULT; AGED; AGING; ARTICLE; BODY HEIGHT; BODY MASS; BODY WEIGHT; BREAST CANCER; CANCER PATIENT; DISEASE ASSOCIATION; FEMALE; HUMAN; INFLAMMATION; LUNG METASTASIS; MAJOR CLINICAL STUDY; MASS SPECTROMETRY; OBESITY; PRIORITY JOURNAL; PROTEIN URINE LEVEL; QUESTIONNAIRE; SMOKING;

ADULT; AGED; AGING; BIOLOGICAL MARKERS; BREAST NEOPLASMS; CASE-CONTROL STUDIES; FEMALE; HUMANS; INFLAMMATION; LUNG NEOPLASMS; MIDDLE AGED; OBESITY; PROGNOSIS; PROSTAGLANDINS; RISK FACTORS; YOUNG ADULT;

EID: 84877251675     PISSN: 19406207     EISSN: 19406215     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-12-0431     Document Type: Article

References (41)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61:69-90.
2. Paget S. The distribution of secondary growths in cancer of the breast. Lancet 1889; 1:571-3.
3. Morris PG, McArthur HL, Hudis CA. Therapeutic options for metastatic breast cancer. Expert Opin Pharmacother 2009; 10:967-81.
4. Carter CL, Allen C, Henson DE. Relation of tumor size, lymph nodestatus, and survival in 24,740 breast cancer cases. Cancer 1989; 63:181-7. (Pubitemid 19032001)
5. Guy CT, Webster MA, Schaller M, Parsons TJ, Cardiff RD, Muller WJ. Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease. Proc Natl Acad Sci U S A 1992; 89:10578-82.
6. Morris PG, McArthur HL, Hudis CA. Breast metastasis. In: Lyden D, Welch D, Psaila B. editors. Cancer metastasis: biologic basis and therapeutics. New York, NY: Cambridge University Press; 2010. p. 425-437.
7. Minn AJ, Gupta GP, Siegel PM, Bos PD, Shu W, Giri DD, et al. Genesthat mediate breast cancer metastasis to lung. Nature 2005; 436:518-24. (Pubitemid 41112921)
8. Gupta GP, Nguyen DX, Chiang AC, Bos PD, Kim JY, Nadal C, et al. Mediators of vascular remodelling co-opted for sequential steps in lung metastasis. Nature 2007; 446:765-70. (Pubitemid 46582040)
9. Taranova AG, Maldonado D III, Vachon CM, Jacobsen EA, Abdala Valencia H, McGarry MP, et al. Allergic pulmonary inflammation promotes the recruitment of circulating tumor cells to the lung. Cancer Res 2008; 68:8582-9.
10. Stathopoulos GT, Sherrill TP, Han W, Sadikot RT, Yull FE, Blackwell TS, et al. Host nuclear factor-kappaB activation potentiates lung cancer metastasis. Mol Cancer Res 2008; 6:364-71. (Pubitemid 351416527)
11. Martey CA, Pollock SJ, Turner CK, O'Reilly KM, Baglole CJ, Phipps RP, et al. Cigarette smoke induces cyclooxygenase-2 and microsomal prostaglandin E2 synthase in human lung fibroblasts: implications for lung inflammation and cancer. Am J Physiol Lung Cell Mol Physiol 2004; 287:L981-91. (Pubitemid 39391028)
12. Scanlon EF, Suh O, Murthy SM, Mettlin C, Reid SE, Cummings KM. Influence of smoking on the development of lung metastases from breast cancer. Cancer 1995; 75:2693-9.
13. Calle EE, Miracle-McMahill HL, Thun MJ, Heath CW Jr. Cigarette smoking and risk of fatal breast cancer. Am J Epidemiol 1994; 139:1001-7. (Pubitemid 24156696)
14. Murin S, Pinkerton KE, Hubbard NE, Erickson K. The effect of cigarette smoke exposure on pulmonary metastatic disease in a murine model of metastatic breast cancer. Chest 2004; 125:1467-71. (Pubitemid 38501364)
15. Chen Y, Chen P, Hanaoka M, Droma Y, Kubo K. Enhanced levels of prostaglandin E2 and matrix metalloproteinase-2 correlate with the severity of airflow limitation in stable COPD. Respirology 2008; 13: 1014-21.
16. Taha R, Olivenstein R, Utsumi T, Ernst P, Barnes PJ, Rodger IW, et al. Prostaglandin H synthase 2 expression in airway cells from patients with asthma and chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000; 161:636-40. (Pubitemid 30129478)
17. Montuschi P, Kharitonov SA, Ciabattoni G, Barnes PJ. Exhaled leukotrienes and prostaglandins in COPD. Thorax 2003; 58:585-8. (Pubitemid 36808128)
18. Murphey LJ, Williams MK, Sanchez SC, Byrne LM, Csiki I, Oates JA, et al. Quantification of the major urinary metabolite of PGE2 by a liquid chromatographic/mass spectrometric assay: determination of cyclooxygenase- specific PGE2 synthesis in healthy humans and those with lung cancer. Anal Biochem 2004; 334:266-75. (Pubitemid 39370961)
19. Gross ND, Boyle JO, Morrow JD, Williams MK, Moskowitz CS, Subbaramaiah K, et al. Levels of prostaglandin E metabolite, the major urinary metabolite of prostaglandin E2, are increased in smokers. Clin Cancer Res 2005; 11:6087-93. (Pubitemid 41170341)
20. Duffield-Lillico AJ, Boyle JO, Zhou XK, Ghosh A, Butala GS, Subbaramaiah K, et al. Levels of prostaglandin E metabolite and leukotriene E (4) are increased in the urine of smokers: evidence that celecoxib shunts arachidonic acid into the 5-lipoxygenase pathway. Cancer Prev Res 2009; 2:322-9.
21. Sterz K, Scherer G, Ecker J. A simple and robust UPLC-SRM/MS method to quantify urinary eicosanoids. J Lipid Res 2012; 53:1026-36.
22. Cleary MP, Grossmann ME. Minireview: Obesity and breast cancer: the estrogen connection. Endocrinology 2009; 150:2537-42.
23. Ewertz M, Jensen MB, Gunnarsdottir KA, Hojris I, Jakobsen EH, Nielsen D, et al. Effect of obesity on prognosis after early-stage breast cancer. J Clin Oncol 2011; 29:25-31.
24. Li CI, Daling JR, Malone KE. Incidence of invasive breast cancer by hormone receptor status from 1992 to 1998. J Clin Oncol 2003; 21: 28-34.
25. Murin S, Inciardi J. Cigarette smoking and the risk of pulmonary metastasis from breast cancer. Chest 2001; 119:1635-40. (Pubitemid 32744915)
26. Khatcheressian JL, Wolff AC, Smith TJ, Grunfeld E, Muss HB, Vogel VG, et al. American Society of Clinical Oncology 2006 update of the breast cancer follow-up and management guidelines in the adjuvant setting. J Clin Oncol 2006; 24:5091-7. (Pubitemid 46631413)
27. Wang D, Dubois RN. Eicosanoids and cancer. Nat Rev Cancer 2010; 10:181-93.
28. Subbaramaiah K, Norton L, Gerald W, Dannenberg AJ. Cyclooxygenase-2 is overexpressed in HER-2/neu-positive breast cancer: evidence for involvement of AP-1 and PEA3. J Biol Chem 2002; 277:18649-57. (Pubitemid 34952420)
29. Minn AJ, Gupta GP, Padua D, Bos P, Nguyen DX, Nuyten D, et al. Lung metastasis genes couple breast tumor size and metastatic spread. Proc Natl Acad Sci U S A 2007; 104:6740-5. (Pubitemid 47175571)
30. Hughes D, Otani T, Yang P, Newman RA, Yantiss RK, Altorki NK, et al. NAD+-dependent 15-hydroxyprostaglandin dehydrogenase regulates levels of bioactive lipids in non-small cell lung cancer. Cancer Prev Res 2008; 1:241-9.
31. Dohadwala M, Yang SC, Luo J, Sharma S, Batra RK, Huang M, et al. Cyclooxygenase-2-dependent regulation of E-cadherin: prostaglandin E(2) induces transcriptional repressors ZEB1 and snail in non-small cell lung cancer. Cancer Res 2006; 66:5338-45. (Pubitemid 43844959)
32. Bachelot T, Ray-Coquard I, Menetrier-Caux C, Rastkha M, Duc A, Blay JY. Prognostic value of serum levels of interleukin 6 and of serum and plasma levels of vascular endothelial growth factor in hormone-refractory metastatic breast cancer patients. Br J Cancer 2003; 88:1721-6. (Pubitemid 36760416)
33. Subbaramaiah K, Howe LR, Bhardwaj P, Du B, Gravaghi C, Yantiss RK, et al. Obesity is associated with inflammation and elevated aromatase expression in the mouse mammary gland. Cancer Prev Res 2011; 4: 329-46.
34. Morris PG, Hudis CA, Giri D, Morrow M, Falcone DJ, Zhou XK, et al. Inflammation and increased aromatase expression occur in the breast tissue of obese women with breast cancer. Cancer Prev Res 2011; 4: 1021-9.
35. Subbaramaiah K, Morris PG, Zhou XK, Morrow M, Du B, Giri D, et al. Increased levels of COX-2 and prostaglandin E2 contribute to elevated aromatase expression in inflamed breast tissue of obese women. Cancer Discov 2012; 2:356-65.
36. Li CW, Xia W, Huo L, Lim SO, Wu Y, Hsu JL, et al. Epithelial-mesenchymal transition induced by TNF-alpha requires NF-kappaBmediated transcriptional upregulation of Twist1. Cancer Res 2012; 72: 1290-300.
37. Sinicrope FA, Dannenberg AJ. Obesity and breast cancer prognosis: weight of the evidence. J Clin Oncol 2011; 29:4-7.
38. Bruunsgaard H, Pedersen M, Pedersen BK. Aging and proinflammatory cytokines. Curr Opin Hematol 2001; 8:131-6. (Pubitemid 32324632)
39. Wang M, Zukas AM, Hui Y, Ricciotti E, Pure E, Fitz Gerald GA. Deletion of microsomal prostaglandin E synthase-1 augments prostacyclin and retards atherogenesis. Proc Natl Acad Sci U S A 2006; 103:14507-12. (Pubitemid 44484780)
40. Singer II, Kawka DW, Schloemann S, Tessner T, Riehl T, Stenson WF. Cyclooxygenase 2 is induced in colonic epithelial cells in inflammatory bowel disease. Gastroenterology 1998; 115:297-306. (Pubitemid 28363422)
41. Altorki NK, Port JL, Zhang F, Golijanin D, Thaler HT, Duffield-Lillico AJ, et al. Chemotherapy induces the expression of cyclooxygenase-2 in non-small cell lung cancer. Clin Cancer Res 2005; 11:4191-7. (Pubitemid 40791585)